Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Hepatology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2014.08.024PMID 25152204PMCID PMC4530584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

  2014cited by this paper
• FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl Rats

  2013cited by this paper
• Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure

  2012cited by this paper
• Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

  2012cited by this paper
• FXR ligands protect against hepatocellular inflammation via SOCS3 induction.

  2012cited by this paper
• Targeting Nuclear Bile Acid Receptors for Liver Disease

  2011cited by this paper
• Angiotensin II and NADPH Oxidase Increase ADMA in Vascular Smooth Muscle Cells

  2010cited by this paper
• Role of Dimethylarginine Dimethylaminohydrolases in the Regulation of Endothelial Nitric Oxide Production*

  2009cited by this paper
• Vascular biology and pathobiology of the liver: Report of a single‐topic symposium

  2008cited by this paper
• FXR-mediated regulation of eNOS expression in vascular endothelial cells.

  2008cited by this paper
• Evidence for the Pathophysiological Role of Endogenous Methylarginines in Regulation of Endothelial NO Production and Vascular Function*

  2007cited by this paper
• Endotoxemia produces coma and brain swelling in bile duct ligated rats

  2007cited by this paper
• Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure

  2007cited by this paper
• Disruption of methylarginine metabolism impairs vascular homeostasis

  2007cited by this paper
• Hydrodynamic gene delivery: its principles and applications.

  2007cited by this paper
• Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis.

  2007cited by this paper
• Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis

  2007cited by this paper
• Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

  2006cited by this paper
• The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo

  2006cited by this paper
• Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation*

  2006cited by this paper
• Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes.

  2006cited by this paper
• Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosis.

  2006cited by this paper
• Dimethylarginine Dimethylaminohydrolase 2 Increases Vascular Endothelial Growth Factor Expression Through Sp1 Transcription Factor in Endothelial Cells

  2006cited by this paper
• Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension

  2005cited by this paper
• Overexpression of Dimethylarginine Dimethylaminohydrolase Reduces Tissue Asymmetric Dimethylarginine Levels and Enhances Angiogenesis

  2005cited by this paper
• Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis.

  2004cited by this paper
• The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

  2004cited by this paper
• Continuous infusion versus intermittent bolus of ceftazidime for the treatment of nosocomial pneumonia

  2003cited by this paper
• Histopathology of portal hypertension: a practical guideline

  2003cited by this paper
• Evidence for Dysregulation of Dimethylarginine Dimethylaminohydrolase I in Chronic Hypoxia–Induced Pulmonary Hypertension

  2003cited by this paper
• High‐level expression of naked DNA delivered to rat liver via tail vein injection

  2002cited by this paper
• Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat.

  1999cited by this paper
• Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension.

  1998cited by this paper
• Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids.

  1997cited by this paper
• Nitric oxide modulates hepatic vascular tone in normal rat liver.

  1994cited by this paper
• Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat.

  1990cited by this paper

• Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders

  2025cites this paper
• From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension

  2025cites this paper
• Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats

  2024cites this paper
• The components of arginine and methylarginine metabolism are indicative of altered kidney function in intrauterine growth-restricted neonates

  2024cites this paper
• Gene coexpression network analysis reveals the genes and pathways in pectoralis major muscle and liver associated with wooden breast in broilers

  2024cites this paper
• DDAH1 recruits peroxiredoxin 1 and sulfiredoxin 1 to preserve its activity and regulate intracellular redox homeostasis

  2024cites this paper
• Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)

  2024cites this paper
• Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF.

  2023cites this paper
• 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.

  2023cites this paper
• Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances

  2023cites this paper
• Emerging Therapeutic Targets for Portal Hypertension

  2023cites this paper
• Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis

  2023cites this paper
• Hepatic DDAH1 mitigates hepatic steatosis and insulin resistance in obese mice: Involvement of reduced S100A11 expression

  2023cites this paper
• Schisantherin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice.

  2023cites this paper
• DDAH1 Protects against Acetaminophen-Induced Liver Hepatoxicity in Mice

  2022cites this paper
• The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis

  2022cites this paper
• Recent advances on FXR-targeting therapeutics.

  2022cites this paper
• Investigational drugs in early clinical development for portal hypertension

  2022cites this paper
• Portal Hypertension in Nonalcoholic Fatty Liver Disease: From Pathogenesis to Clinical Practice

  2022cites this paper
• Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

  2022influential citation
• Alleviation of liver cirrhosis and associated portal-hypertension by Astragalus species in relation to their UPLC-MS/MS metabolic profiles: a mechanistic study

  2022cites this paper
• Fluxomics reveals cellular and molecular basis of increased renal ammoniagenesis

  2022cites this paper
• Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma.

  2021cites this paper
• The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

  2021cites this paper
• DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage

  2021cites this paper
• Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis

  2021cites this paper
• Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury

  2021cites this paper
• Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease

  2020cites this paper
• Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.

  2020cites this paper
• Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease

  2020cites this paper
• Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC

  2019cites this paper
• Vascular Targets for the Treatment of Portal Hypertension

  2019cites this paper
• Novel Targets and Drug Development in Portal Hypertension

  2019cites this paper
• Future Medical Treatment of PSC

  2019cites this paper
• Research progress on signaling pathways in cirrhotic portal hypertension

  2018cites this paper
• Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Hepatic microcirculation and mechanisms of portal hypertension

  2018cites this paper
• Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy.

  2018cites this paper
• Title Farnesoid X receptor agonist treatment alters bile acid metabolism but exacerbates liver damage in a piglet model of short-bowel syndrome

  2018cites this paper
• The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury

  2018cites this paper
• Establishment of a CRISPR/Cas9‐Mediated Cysltr1 Knockout Mouse Model and iTRAQ‐Based Proteomic Analysis

  2018cites this paper
• The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

  2017cites this paper
• Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats

  2017cites this paper
• Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].

  2017cites this paper
• Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome

  2017cites this paper
• Novel treatment options for portal hypertension

  2017cites this paper
• Steroidal or non-steroidal FXR agonists - Is that the question?

  2017cites this paper
• Portal Hypertension—Molecular Mechanisms

  2017cites this paper
• New therapeutic concepts in bile acid transport and signaling for management of cholestasis

  2017cites this paper
• Dimethylarginine Dimethylaminohydrolase 1 Protects Against High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice

  2017cites this paper
• Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism butExacerbates Liver Damage in a Piglet Model of Short-BowelSyndrome

  2017cites this paper
• Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.

  2016cites this paper
• Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure

  2016influential citation
• The restorative effect of ascorbic acid on liver injury inducedby asymmetric dimethylarginine

  2016cites this paper
• Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis

  2016cites this paper
• The Molecular Characterisation of Dimethylarginine Dimethylaminohydrolase-1 and Determination of its Role in Portal Hypertension

  2016cites this paper
• What is the role of antifibrotic therapies in the current and future management of NAFLD

  2016cites this paper
• Serum Biomarkers for Evaluating Portal Hypertension

  2016cites this paper
• Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs.

  2016cites this paper
• Emerging therapies for portal hypertension in cirrhosis

  2016cites this paper
• Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?

  2016cites this paper
• Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis

  2016cites this paper
• Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease

  2016cites this paper
• Antitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma

  2015cites this paper
• Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.

  2015cites this paper
• Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH

  2015cites this paper
• Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis.

  2015cites this paper
• Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis

  2015cites this paper
• New cellular and molecular targets for the treatment of portal hypertension

  2015cites this paper
• Nitric oxide in liver diseases.

  2015cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper